NASDAQ: PYPDPolypid Ltd Stock
$3.84+0.04 (+1.05%)
Updated Oct 30, 2025
PYPD Price
$3.84
Fair Value Price
$1.02
Market Cap
$60.11M
52 Week Low
$2.30
52 Week High
$3.93
P/E
0.43x
P/B
2.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.53M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.84
Operating Cash Flow
-$26M
Beta
0.74
Next Earnings
Nov 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PYPD Overview
PolyPid LTD. is developing products based on a polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs and improve surgical results. The company's lead product candidate is D-PLEX100, to prevent sternal (bone) and abdominal (soft tissue) surgical site infections. PolyPid was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PYPD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PYPD
Ranked#220 of 489
Ranked#220 of 489
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $12.12 | A | |
| $7.40 | A |
Be the first to know about important PYPD news, forecast changes, insider trades & much more!
PYPD News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PYPD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PYPD ($3.84) is overvalued by 276.92% relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PYPD ($3.84) is not significantly undervalued (276.92%) relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PYPD was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PYPD due diligence checks available for Premium users.
Valuation
PYPD fair value
Fair Value of PYPD stock based on Discounted Cash Flow (DCF)
Price
$3.84
Fair Value
$1.02
Overvalued by
276.92%
PYPD ($3.84) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PYPD ($3.84) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PYPD was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PYPD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.43x
Industry
-87.09x
Market
40.85x
PYPD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PYPD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PYPD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.94x
Industry
4.97x
PYPD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PYPD's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.0M
Profit Margin
0%
PYPD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$37.7M
Liabilities
$17.2M
Debt to equity
0.84
PYPD's short-term assets ($29.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PYPD's short-term assets ($29.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PYPD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PYPD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PYPD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PYPD vs Biotech Stocks
Polypid Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.